Cargando…

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond

SIMPLE SUMMARY: Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors (PARPi) are effective against tumors with mutations in DNA repair genes, most commonly in the BRCA1 and BRCA2 genes. Because these tumors are unable to repair their DNA, PARPi have been used to target DNA repair pathways...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menezes, Maria Clara Saad, Raheem, Farah, Mina, Lida, Ernst, Brenda, Batalini, Felipe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454726/ https://www.ncbi.nlm.nih.gov/pubmed/36077867 http://dx.doi.org/10.3390/cancers14174332

Ejemplares similares

Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches
por: Raheem, Farah, et al.
Publicado: (2023)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
por: Frizzell, Kristine M, et al.
Publicado: (2009)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
por: Hodgson, Darren R., et al.
Publicado: (2018)

Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies
por: Nerone, Marta, et al.
Publicado: (2023)

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
por: Stossel, Chani, et al.
Publicado: (2023)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors
por: Zahari, Mihaela Mărioara, et al.
Publicado: (2021)

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
por: Cruz, C, et al.
Publicado: (2018)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
por: Keung, Man Yee, et al.
Publicado: (2020)

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
por: Chu, Yu-Yi, et al.
Publicado: (2022)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2018)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
por: Gonçalves, Anthony, et al.
Publicado: (2020)

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor
por: Sahnane, Nora, et al.
Publicado: (2020)

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
por: Shao, Fengping, et al.
Publicado: (2021)

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
por: Dilmac, Sayra, et al.
Publicado: (2023)

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
por: Rafii, Saeed, et al.
Publicado: (2017)

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature
por: Batalini, Felipe, et al.
Publicado: (2023)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

Germline BRCA2 mutations in men with breast cancer.
por: Mavraki, E., et al.
Publicado: (1997)

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
por: Castroviejo‐Bermejo, Marta, et al.
Publicado: (2018)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer
por: Henouda, Sarra, et al.
Publicado: (2016)

BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
por: Vos, Shoko, et al.
Publicado: (2017)

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
por: Blum, Joanne L., et al.
Publicado: (2022)

Screening for germline rearrangements in BRCA1 and BRCA2 in Norwegian families with breast or breast/ovarian cancer
por: Van Ghelue, M, et al.
Publicado: (2005)

Is Breast Conserving Surgery Efficacious in Breast Cancer Patients with BRCA1 or BRCA2 Germline Mutation?
por: Emiroglu, Selman, et al.
Publicado: (2023)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
por: Min, Ahrum, et al.
Publicado: (2020)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
por: Du, Tingting, et al.
Publicado: (2022)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance
por: Pandya, Deep, et al.
Publicado: (2021)

PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
por: De Soto, Joseph A., et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_h27uo70ilcb57fldf2jrmf80v9